AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Predictors of Relapse in Major Depressive Disorder (PERFORM-D)

Recruitingn/aAges 18 Years - 70 YearsAllAbraham Nunes
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Major depressive disorder (MDD) is a common condition involving recurring periods of depression. One of the major challenges faced by people with MDD is that the episodes of depression tend to recur even after they are successfully treated. Currently, it is hard to predict when a depressive episode will recur. Being able to forecast this would help healthcare providers monitor patients and prevent relapse. The purpose of this study is to monitor features such as clinical symptoms, physical activity, sleep patterns, cognitive functioning and brain activity to help us understand how relapse happens and the mechanisms that cause it. From these different types of data, investigators will build a model that tells us who is more likely to experience a relapse and when the relapse is likely to occur. This study will be a significant step forward in understanding and managing MDD. Investigator

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Outpatients 18 to 70 years of age. * Meet DSM-V criteria for MDD as determined by the SCID-5 or other standardized clinical interviews. * In the current or most recent MDE, participant must be responding or responded to a treatment or a combination of treatments for MDD. Patients with remitted MDD who are currently not taking medications will also be accepted. Patients must have achieved remission at or later than May 1, 2023. * Participants must have a MADRS total score โ‰ค14. * Participant must be willing and able to complete self-reported assessments including sufficient fluency in English. * Participant must be willing to wear the wrist-worn actigraphic device for the duration of the study. Exclusion Criteria: * Bipolar I or Bipolar-II diagnosis (lifetime), schizophrenia, or schizoaffective disorder. * Elevated risk of suicide, as determined by clinical evaluation. * Existence of major neurological disorders, head injury (if accompanied by any of \[A\] loss of consciousness longer than 24 hours, \[B\] documented evidence of Glasgow Coma Scale \<9 at the time of injury, \[C\] post-traumatic amnesia lasting longer than 24 hours) (43), or other unstable medical conditions. * The participant presents with any condition which, according to the researcher's judgment, could interfere with the assessments stipulated in the protocol. * The participant is employed by the researcher, actively involved in the current study or other research overseen by the same researcher, or is a relative of a study employee or the researcher.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

9 sites
University of Calgary
Calgary, Canada
University of British Columbia
Vancouver, Canada
Nova Scotia Health
Halifax, Canada
McMaster University
Hamilton, Canada
Queen's University
Kingston, Canada
The Royal Ottawa Mental Health Centre
Ottawa, Canada
Centre for Addiction and Mental Health (CAMH)
Toronto, Canada
University Health Network
Toronto, Canada

โ€ฆand 1 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy